Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M284Revenue $M45.2Net Margin (%)-1,466.6Altman Z-Score-1.0
Enterprise Value $M194EPS $-0.6Operating Margin %-1,493.4Piotroski F-Score4
P/E(ttm)--Beneish M-Score-8.7Pre-tax Margin (%)-1,491.9Higher ROA y-yN
Price/Book3.010-y EBITDA Growth Rate %--Quick Ratio9.9Cash flow > EarningsY
Price/Sales94.35-y EBITDA Growth Rate %--Current Ratio9.9Lower Leverage y-yY
Price/Free Cash Flow204y-y EBITDA Growth Rate %-1,014.3ROA % (ttm)-28.9Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-38.2Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M69.8ROIC % (ttm)-301.7Gross Margin Increase y-yN

Gurus Latest Trades with PGNX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PGNXKen Fisher 2015-12-31 Add$5.5 - $8.16
($6.57)
$ 4.07-38%Add 68.40%140,191
PGNXKen Fisher 2015-09-30 Buy $5.48 - $9.42
($7.67)
$ 4.07-47%New holding83,250
PGNXJulian Robertson 2015-06-30 Sold Out -1.29%$4.95 - $7.82
($6.05)
$ 4.07-33%Sold Out0
PGNXJulian Robertson 2014-09-30 Buy 1.8%$4.15 - $5.56
($4.99)
$ 4.07-18%New holding1,290,055
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PGNX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


PGNX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ISRAEL ROBERT JExecutive Vice President, Medi 2015-06-11Sell2,000$6.83-40.41view
ISRAEL ROBERT JExecutive Vice President, Medi 2015-03-13Sell3,000$7-41.86view
ISRAEL ROBERT JExecutive Vice President, Medi 2015-03-11Sell2,000$6.83-40.41view
ISRAEL ROBERT JExecutive Vice President, Medi 2015-03-03Sell5,000$6.49-37.29view
ISRAEL ROBERT JExecutive Vice President, Medi 2015-01-12Sell2,000$7.06-42.35view
ISRAEL ROBERT JExecutive Vice President, Medi 2014-12-11Sell3,000$7.07-42.43view
ISRAEL ROBERT JExecutive Vice President, Medi 2014-11-21Sell9,000$7-41.86view
ISRAEL ROBERT JExecutive Vice President, Medi 2014-11-13Sell10,000$6.83-40.41view
ISRAEL ROBERT JExecutive Vice President, Medi 2014-11-11Sell5,000$6.53-37.67view
Broadfin Healthcare Master Fun10% Owner 2014-07-21Buy1,625,436$4.6-11.52view

Quarterly/Annual Reports about PGNX:

    News about PGNX:

    Articles On GuruFocus.com
    Tiger Management’s Julian Robertson Buys Alibaba, eBay, MasTec, Sells Tableau Software, Monsanto, Nov 14 2014 
    Ex-Boxer Paul Tudor Jones Delivering Knockout Punches on Wall Street Nov 07 2014 
    Weekly CEO Buys Highlight: CVRR, HBAN, VVTV, SXCP, PGNX Jan 27 2013 
    Weekly CEO Buys Highlight: SUSP, ROVI, ZLC, MDW, PGNX Oct 01 2012 
    5 Stocks That Dropped the Most Since Gurus Bought Them Sep 13 2012 
    Dendreon Could Push Higher If New Drug Trials Succeed Apr 23 2012 
    Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Dec 01 2010 
    Progenics Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
    Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Nov 02 2010 
    Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Oct 04 2010 

    More From Other Websites
    Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) Phase III Clinical Trial Expected; Analyst Report Feb 09 2016
    Progenics Pharmaceuticals to Present at Upcoming Investor Conferences Feb 01 2016
    Progenics Pharmaceuticals to Present at Upcoming Investor Conferences Feb 01 2016
    Biotechnology Stocks Technical Data -- Regulus Therapeutics, Progenics Pharma, Spectrum Pharma, and... Jan 12 2016
    Progenics Pharmaceuticals Commences Pivotal Phase 3 Study of PSMA Targeted Imaging Agent 1404 for... Jan 07 2016
    Progenics Pharmaceuticals Commences Pivotal Phase 3 Study of PSMA Targeted Imaging Agent 1404 for... Jan 07 2016
    PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement Jan 05 2016
    PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Completion of Acquisition or Disposition of... Dec 28 2015
    Technical Coverage on Biotechnology Stocks - Agenus, Progenics Pharma, Arrowhead Research, and... Dec 28 2015
    Progenics Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 21 2015
    PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Dec 18 2015
    Stock Updates on Biotechnology -- Xenoport, Progenics Pharma, Ocata Therapeutics, and Vanda Pharma Dec 17 2015
    PROGENICS PHARMACEUTICALS INC Financials Dec 08 2015
    Progenics (PGNX) Reaches Target Enrolment in Azedra Study Dec 04 2015
    PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Dec 04 2015
    Progenics Pharmaceuticals Achieves Target Enrollment in its Phase 2b Pivotal Trial of Azedra™ Dec 03 2015
    Progenics Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PGNX) : December 1, 2015 Dec 01 2015
    Progenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : December 1,... Dec 01 2015
    Here is What Hedge Funds Think About Memorial Production Partners LP (MEMP) Nov 30 2015
    Progenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : November... Nov 20 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK